Dark

Check out our API

CALA
CALITHERA BIOSCIENCES INC
stock OTC

EOD

Feb 24, 2026

0.000200USD-42.857%(-0.000150)100

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 Benzinga

07:57AM EST Ladenburg Thalmann Initiates Coverage On Calithera Biosciences with Buy Rating, Announces Price Target of $4 Benzinga

Jan 20, 2022

10:41AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 Benzinga

07:40AM EST The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). RTTNews

06:15AM EST SVB Leerink Upgrades Calithera Biosciences to Outperform, Raises Price Target to $3 Benzinga

06:15AM EST Calithera Biosciences Shares Spike Higher; Hearing SVB Leerink Upgrades Stock From Market Perform To Outperform and Raised Its Price Target From $1 to $3 Benzinga

Jan 7, 2022

07:01AM EST AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel PR Newswire

Jan 5, 2022

04:01PM EST Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference. GlobeNewswire Inc

Dec 17, 2021

02:08PM EST Calithera Bioscience Granted European Patent Titled 'ARGINASE INHIBITOR COMBINATION THERAPIES' Benzinga

Nov 12, 2021

07:00AM EST Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. GlobeNewswire Inc

05:33AM EST Calithera Biosciences CEO Susan Molineaux Reported Purchase of 100,000 Shares @ Avg Price of $0.85/Share in Form 4 Filing on Thursday Benzinga

Nov 10, 2021

09:07PM EST Calithera Biosciences CEO Susan Molineaux Reported Purchase of 100,000 Shares @ Avg Price: of $0.85/Share in Form 4 Filing on Wednesday Benzinga

Nov 9, 2021

05:20PM EST Calithera Biosciences Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M Benzinga

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

06:08AM EST HC Wainwright & Co. Downgrades Calithera Biosciences to Neutral Benzinga

Nov 5, 2021

11:56AM EDT William Blair Downgrades Calithera Biosciences to Market Perform Benzinga

09:43AM EDT The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill Benzinga

09:39AM EDT Calithera Biosciences Promotes Emil T. Kuriakose, MD, To Chief Medical Officer Benzinga

09:39AM EDT Calithera Biosciences Announces Decision To Discontinue KEAPSAKE Clinical Trial; Says Interim Analysis Demonstrated Lack Of Clinical Benefit Among Patients Treated With Telaglenastat Benzinga

07:00AM EDT Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the promotion of current vice president and head of clinical development, Dr. Emil T. Kuriakose, to chief medical officer (CMO). Dr. Kuriakose will succeed Dr. Keith Orford, who has been appointed to Calitheras board of directors. GlobeNewswire Inc

07:00AM EDT --KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat GlobeNewswire Inc

Nov 1, 2021

07:16AM EDT Calithera Presents Interim Data From Phase 1b Trial Of Arginase Inhibitor CB-280 In Cystic Fibrosis RTTNews

07:04AM EDT Calithera Highlights Presentation Of Interim Data From Phase 1b Trial Pf Arginase Inhibitor CB-280 In Cystic Fibrosis At NACFC 2021 Benzinga

07:00AM EDT -- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride-- Early positive trend seen in FEV1, a safety endpoint GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 21, 2021

12:11PM EDT Calithera Biosciences To Present First Clinical Data From Development Program For Arginase Inhibitor CB-280 At NACFC 2021 Benzinga

08:00AM EDT Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the companys investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021. GlobeNewswire Inc

Oct 19, 2021

08:23AM EDT The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio Benzinga

06:51AM EDT Calithera Buys Two Oncology Candidates From Takeda For $45M Benzinga

Oct 18, 2021

04:08PM EDT Calithera Biosciences Reports Purchase Of 2 Clinical-Stage Assets From Takeda Pharma For $10M In Upfront Cash Payment, Up To $35M In Series A Preferred Shares Benzinga

04:07PM EDT -- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Companys precision oncology pipeline -- GlobeNewswire Inc

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 8, 2021

07:00AM EDT Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in GlobeNewswire Inc

Sep 2, 2021

07:00AM EDT Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its participation in two upcoming virtual healthcare investor conferences. GlobeNewswire Inc

Aug 5, 2021

05:51PM EDT Calithera Biosciences Q2 EPS $(0.19) Beats $(0.24) Estimate, Sales $3.00M Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 29, 2021

07:00AM EDT Calithera Biosciences to Report Second Quarter 2021 Financial GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jun 7, 2021

08:02AM EDT Calithera Biosciences Highlights Presentation Of Data From Phase 2 CANTATA Study At 2021 ASCO Annual Meeting Benzinga

08:00AM EDT Final Data from Calithera Biosciences Phase 2 GlobeNewswire Inc

May 27, 2021

07:00AM EDT Calithera to Present at the Jefferies 2021 Virtual Healthcare GlobeNewswire Inc

May 17, 2021

10:08AM EDT Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings Benzinga

08:26AM EDT Antengene And Calithera Biosciences Enter Into Worldwide Exclusive License Agreement To Develop And Commercialize CD73 Inhibitor CB-708 (ATG-037); Calithera To Receive Upfront Payment And Potential Milestones, Amount Not Disclosed Benzinga

08:23AM EDT Biotechnology company Calithera Biosciences, Inc. (CALA) and Hong Kong-based Antengene Corp. announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera's small molecule inhibitor of CD73. RTTNews

08:16AM EDT Calithera Biosciences and Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708; Calithera Will Receive An Upfront Payment Of $255M Benzinga

08:12AM EDT Calithera Biosciences And Antengene Enter Exclusive License Agreement For Development Of CB-708 RTTNews

08:00AM EDT --CB-708 is an oral small molecule inhibitor of CD73 in preclinical development for oncology--Antengene is granted exclusive rights to develop and commercialize asset discovered and initially developed by Calithera GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 6, 2021

05:14PM EDT Calithera Biosciences Q1 EPS $(0.28) Up From $(0.38) YoY Benzinga

Apr 30, 2021

07:00AM EDT Calithera Biosciences to Report First Quarter 2021 Financial GlobeNewswire Inc

Apr 28, 2021

07:13AM EDT Calithera Biosciences Says Results From Co's CANTATA Study To Be Presented At 2021 ASCO Annual Meeting Benzinga

07:00AM EDT Results from Calithera Biosciences CANTATA Study GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 16, 2021

04:09PM EDT Calithera Biosciences Q4 EPS $(0.32), Inline Benzinga

04:06PM EDT --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- GlobeNewswire Inc

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

04:46AM EDT Earnings Scheduled For March 16, 2021 Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 12, 2021

03:10PM EST UPDATE Calithera Biosciences to Report Fourth GlobeNewswire Inc

Mar 10, 2021

07:05AM EST Calithera Biosciences to Report Fourth Quarter 2021 Financial GlobeNewswire Inc

Mar 2, 2021

07:00AM EST Calithera to Present at the H.C. Wainwright Virtual Global Life GlobeNewswire Inc

Feb 22, 2021

07:00AM EST Calithera to Participate in the 10th Annual SVB Leerink Global GlobeNewswire Inc

Jan 25, 2021

04:26PM EST Calithera Biosciences 13G From Adage Capital Shows New 5.67% Stake In Co. Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 11, 2021

05:06PM EST INCB001158 Biliary Tract Cancer Data To Be Presented At 2021 Virtual ASCO Gastrointestinal Cancers Symposium Benzinga

05:03PM EST INCB001158 Biliary Tract Cancer Data to be Presented at 2021 GlobeNewswire Inc

Jan 5, 2021

10:11AM EST Benzinga's Top Upgrades, Downgrades For January 5, 2021 Benzinga

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

08:26AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

07:04AM EST Calithera to Present at the H.C. Wainwright Virtual BioConnect GlobeNewswire Inc

06:20AM EST HC Wainwright & Co. Maintains Buy on Calithera Biosciences, Lowers Price Target to $4 Benzinga

04:40AM EST SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2 Benzinga

Jan 4, 2021

02:30PM EST Mid-Afternoon Market Update: Dow Tumbles Over 500 Points; Calithera Biosciences Shares Slide Benzinga

02:15PM EST Mid-Morning Market Update: Markets Down; US Manufacturing PMI Rises To 57.1 In December Benzinga

12:13PM EST Mid-Day Market Update: Crude Oil Down Over 2%; The9 Shares Spike Higher Benzinga

10:55AM EST Shares of Calithera Biosciences, Inc. (CALA) are currently slipping over 40% after the company said its trial of Telaglenastat in renal cell carcinoma did not achieve primary endpoint. RTTNews

10:21AM EST Mid-Morning Market Update: Markets Down; US Manufacturing PMI Rises To 57.1 In December Benzinga

07:24AM EST Calithera Biosciences' CANTATA Trial Fails To Achieve RTTNews

07:13AM EST Calithera: CANTATA Study Of Telaglenastat In Renal Cell Carcinoma Did Not Achieve Primary Endpoint RTTNews

07:09AM EST Calithera Biosciences Say Will Continue To Advance Telaglenastat KEAPSAKE Trial In Non-Small Cell Lung Cancer, Arginase Inhibitor Cb-280 Trial In Cystic Fibrosis, Emerging Pipeline Benzinga

07:08AM EST Calithera Biosciences Reports CANTATA Study Of Telaglenastat In Renal Cell Carcinoma Did Not Achieve Primary Endpoint; Co. To Reduce Workforce By ~35% Benzinga

07:00AM EST -- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline GlobeNewswire Inc

Dec 31, 2020

04:55PM EST Calithera Biosciences Announces New Employment Inducement Grant GlobeNewswire Inc

Nov 11, 2020

07:01AM EST Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November. GlobeNewswire Inc

Nov 9, 2020

07:00AM EST Calithera Biosciences Presents New Preclinical Data for CB-668 at GlobeNewswire Inc

Nov 5, 2020

05:32PM EST Calithera Biosciences Q3 EPS $(0.32) Misses $(0.31) Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 4, 2020

01:08PM EST Calithera Biosciences Announces Expansion Of Ongoing Clinical Trial Evaluating Telaglenastat In Combination With Palbociclib Benzinga

01:05PM EST Calithera Biosciences Announces Expansion of Ongoing Clinical GlobeNewswire Inc

Nov 2, 2020

04:09PM EST Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga

04:07PM EST Calithera Biosciences Announces New Employment Inducement Grants GlobeNewswire Inc

08:04AM EST Calithera Biosciences Receives Up to $2.4M From teh Cystic Fibrosis Foundation Benzinga

08:04AM EST Calithera Biosciences Awarded Up To $2.4M From Cystic Fibrosis Foundation To Support Clinical Development Of Arginase Inhibitor, CB-280 Benzinga

08:00AM EST Calithera Biosciences Awarded up to $2.4M from Cystic Fibrosis GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

07:01AM EDT Calithera Biosciences to Report Third Quarter 2020 Financial GlobeNewswire Inc

Oct 7, 2020

08:27AM EDT Calithera Biosciences Reports CB-280 Arginase Inhibitor Trial In Progress Poster Presented At North American Cystic Fibrosis Virtual Conference Benzinga

08:08AM EDT Calithera Biosciences CB-280 Arginase Inhibitor GlobeNewswire Inc

Oct 2, 2020

07:14AM EDT Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RTTNews

07:01AM EDT Calithera Biosciences Announces New Employment Inducement Grant GlobeNewswire Inc

Sep 24, 2020

07:28AM EDT Calithera Begins KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat Plus Chemoimmunotherapy RTTNews

07:09AM EDT Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat In Combination With Chemoimmunotherapy To Treat Aggressive Form Of Lung Cancer Benzinga

07:00AM EDT - Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting amongpatients with non-small cell lung cancer and a mutation in the KEAP1/NRF2pathway GlobeNewswire Inc

Sep 4, 2020

07:00AM EDT Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the company will participate in four upcoming virtual healthcare investor conferences. GlobeNewswire Inc

Sep 2, 2020

07:01AM EDT Calithera Biosciences Announces New Employment Inducement Grant GlobeNewswire Inc

Aug 11, 2020

04:59AM EDT SVB Leerink Maintains Outperform on Calithera Biosciences, Lowers Price Target to $7 Benzinga

Aug 10, 2020

04:07PM EDT Calithera Biosciences Q2 EPS $(0.29) Beats $(0.33) Estimate Benzinga

04:06PM EDT --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 3, 2020

07:16AM EDT Calithera Reports New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) RTTNews

07:03AM EDT Calithera Biosciences Announces New Employment Inducement Grant GlobeNewswire Inc

Jul 28, 2020

07:00AM EDT Calithera Biosciences to Report Second Quarter 2020 Financial GlobeNewswire Inc

Jul 14, 2020

07:00AM EDT Calithera Biosciences announced today the appointment of Scott Garland to its board of directors. Garland is a 29-year veteran of the biopharmaceutical industry who most recently served as the president and chief executive officer of recently-acquired Portola Pharmaceuticals. GlobeNewswire Inc

Jul 13, 2020

07:11AM EDT Calithera Biosciences Begins Phase 1b Trial Of Arginase Inhibitor CB-280 RTTNews

07:03AM EDT Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis Benzinga

07:00AM EDT Calithera Biosciences Initiates Phase 1b Trial of Arginase GlobeNewswire Inc

Share